Dronedarone induces regression of coronary artery remodeling related to better global antioxidant status

• Published in: Hypertension research 2019-10, Vol.42 (10), p.1485-1494
• Main Authors: Quintana-Villamandos, Begoña, Pazó-Sayós, Laia, Arribas, Silvia Magdalena, Rodríguez-Rodríguez, Pilar, Böger, Rainer H, Lüneburg, Nicole, Delgado-Baeza, Emilio, González, Maria Carmen
• Format: Article
• Language: English
• Subjects: Antioxidants; Coronary vessels; Hypertension; Veins & arteries
• ISSN: 0916-9636; 1348-4214
• DOI: 10.1038/s41440-019-0257-z

Our group previously demonstrated that dronedarone induces regression of left ventricular hypertrophy in spontaneously hypertensive rats (SHRs). We assessed changes in vascular remodeling and oxidative stress following short-term use of this agent. The coronary artery was isolated from 10-month-old male SHRs treated with 100 mg kg dronedarone once daily for 14 days (SHR-D group), and age-matched untreated SHRs were used as hypertensive controls. We analyzed the geometry and composition of the artery and constructed dose-response curves for acetylcholine and serotonin (5-HT). We calculated a global score (OXY-SCORE) from plasma biomarkers of oxidative status: carbonyl levels, thiol levels, reduced glutathione levels, total antioxidant capacity, and superoxide anion scavenging activity. Finally, we analyzed asymmetric dimethylarginine (ADMA) concentrations in plasma. Dronedarone significantly decreased wall thickness (medial and adventitial layer thickness and cell count) and the cross-sectional area of the artery. Dronedarone significantly improved endothelium-dependent relaxation and reduced the contraction induced by 5-HT. The OXY-SCORE was negative in the SHR model group (suggesting an enhanced oxidative status) and was positive in the SHR-D group (suggesting enhanced antioxidant defense). Dronedarone significantly decreased the concentrations of ADMA. We conclude that dronedarone improves coronary artery remodeling in SHRs. The better global antioxidant status after treatment with dronedarone and decreased plasma ADMA levels could contribute to the cardiovascular protective effect of dronedarone.